VXRT inventory forecast 2025 refers back to the predicted efficiency of the inventory of Vaxart, Inc. (VXRT) within the yr 2025. Inventory forecasts try to predict the longer term worth of a inventory based mostly on numerous components resembling the corporate’s monetary efficiency, business developments, and total financial situations.
VXRT is a clinical-stage biotechnology firm targeted on growing oral vaccines for infectious ailments. The corporate’s lead product candidate is VXA-CoV2-1, an oral vaccine for COVID-19. Vaxart has additionally developed oral vaccines for norovirus, seasonal influenza, and respiratory syncytial virus (RSV).
